ellipticine has been researched along with Neuroblastoma in 7 studies
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.
Neuroblastoma: A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two covalent ellipticine-derived DNA adducts, which are associated with cytotoxicity of ellipticine to human UKF-NB-3 and UKF-NB-4 neuroblastoma cell lines, were detected by the (32)P-postlabeling method." | 7.78 | Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique. ( Eckschlager, T; Frei, E; Kizek, R; Poljakova, J; Stiborova, M, 2012) |
| "The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA." | 7.77 | Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. ( Dvorakova, M; Eckschlager, T; Frei, E; Göttlicherova, M; Hrabeta, J; Hrebackova, J; Kizek, R; Kopejtkova, B; Moserova, M; Poljakova, J; Stiborova, M, 2011) |
| "Ellipticine was released from ApoElli into the water environment under pH 6." | 5.51 | Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells. ( Adam, V; Arlt, VM; Černá, T; Dostálová, S; Eckschlager, T; Heger, Z; Hraběta, J; Indra, R; Lengálová, A; Martínková, M; Schmeiser, HH; Stiborová, M; Wilhelm, M, 2019) |
| "Treatment of ellipticine-sensitive UKF-NB-4 and ellipticine-resistant UKF-NB-4ELLI cells with ellipticine-induced cytoplasmic vacuolization and ellipticine is concentrated in these vacuoles." | 5.42 | Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells. ( Adam, V; Cerna, T; Doktorova, H; Eckschlager, T; Frei, E; Groh, T; Hrabeta, J; Khalil, MA; Kizek, R; Poljakova, J; Stiborova, M; Uhlik, J, 2015) |
| "Two covalent ellipticine-derived DNA adducts, which are associated with cytotoxicity of ellipticine to human UKF-NB-3 and UKF-NB-4 neuroblastoma cell lines, were detected by the (32)P-postlabeling method." | 3.78 | Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique. ( Eckschlager, T; Frei, E; Kizek, R; Poljakova, J; Stiborova, M, 2012) |
| "The cytotoxicity of ellipticine to neuroblastomas was increased by pre-treating these cells with VPA or TSA." | 3.77 | Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma. ( Dvorakova, M; Eckschlager, T; Frei, E; Göttlicherova, M; Hrabeta, J; Hrebackova, J; Kizek, R; Kopejtkova, B; Moserova, M; Poljakova, J; Stiborova, M, 2011) |
| "Treatment of ellipticine-sensitive UKF-NB-4 and ellipticine-resistant UKF-NB-4ELLI cells with ellipticine-induced cytoplasmic vacuolization and ellipticine is concentrated in these vacuoles." | 1.42 | Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells. ( Adam, V; Cerna, T; Doktorova, H; Eckschlager, T; Frei, E; Groh, T; Hrabeta, J; Khalil, MA; Kizek, R; Poljakova, J; Stiborova, M; Uhlik, J, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Silalai, P | 1 |
| Pruksakorn, D | 1 |
| Chairoungdua, A | 1 |
| Suksen, K | 1 |
| Saeeng, R | 1 |
| Cerna, T | 3 |
| Hrabeta, J | 5 |
| Eckschlager, T | 6 |
| Frei, E | 4 |
| Schmeiser, HH | 2 |
| Arlt, VM | 2 |
| Stiborová, M | 6 |
| Indra, R | 1 |
| Heger, Z | 1 |
| Wilhelm, M | 1 |
| Dostálová, S | 1 |
| Lengálová, A | 1 |
| Martínková, M | 1 |
| Adam, V | 2 |
| Groh, T | 1 |
| Khalil, MA | 1 |
| Poljakova, J | 4 |
| Kizek, R | 3 |
| Uhlik, J | 1 |
| Doktorova, H | 1 |
| Procházka, P | 1 |
| Libra, A | 1 |
| Zemanová, Z | 1 |
| Hřebačková, J | 2 |
| Bunček, M | 1 |
| Dvorakova, M | 1 |
| Moserova, M | 1 |
| Göttlicherova, M | 1 |
| Kopejtkova, B | 1 |
7 other studies available for ellipticine and Neuroblastoma
| Article | Year |
|---|---|
Synthesis of propargylamine mycophenolate analogues and their selective cytotoxic activity towards neuroblastoma SH-SY5Y cell line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug | 2021 |
The Histone Deacetylase Inhibitor Valproic Acid Exerts a Synergistic Cytotoxicity with the DNA-Damaging Drug Ellipticine in Neuroblastoma Cells.
Topics: Apoptosis; Cell Line, Tumor; Drug Synergism; Ellipticines; Histone Deacetylase Inhibitors; Humans; M | 2018 |
Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoferritins; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; DNA Ad | 2019 |
Vacuolar-ATPase-mediated intracellular sequestration of ellipticine contributes to drug resistance in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chloroquine; DNA Adducts; Drug Resistance, Neopl | 2015 |
Mechanisms of ellipticine-mediated resistance in UKF-NB-4 neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Comparative Genomic Hybridization; DNA Topoisome | 2012 |
Anticancer agent ellipticine combined with histone deacetylase inhibitors, valproic acid and trichostatin A, is an effective DNA damage strategy in human neuroblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; DNA Damage; Dose-Response | 2011 |
Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
Topics: Antineoplastic Agents; Cell Line, Tumor; DNA Adducts; Doxorubicin; Ellipticines; Humans; Isotope Lab | 2012 |